These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25377872)

  • 1. Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease.
    Olson E; Demopoulos L; Haws TF; Hu E; Fang Z; Mahar KM; Qin P; Lepore J; Bauer TA; Hiatt WR
    Vasc Med; 2014 Dec; 19(6):473-82. PubMed ID: 25377872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.
    Creager MA; Olin JW; Belch JJ; Moneta GL; Henry TD; Rajagopalan S; Annex BH; Hiatt WR
    Circulation; 2011 Oct; 124(16):1765-73. PubMed ID: 21947297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA; Krantz MJ; Hiatt WR
    Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication.
    Mohler ER; Gainer JL; Whitten K; Eraso LH; Thanaporn PK; Bauer T
    Vasc Med; 2011 Oct; 16(5):346-53. PubMed ID: 22003000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.
    Hiatt WR; Hirsch AT; Creager MA; Rajagopalan S; Mohler ER; Ballantyne CM; Regensteiner JG; Treat-Jacobson D; Dale RA; Rooke T
    Vasc Med; 2010 Jun; 15(3):171-9. PubMed ID: 20212073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
    Brass EP; Anthony R; Cobb FR; Koda I; Jiao J; Hiatt WR
    J Am Coll Cardiol; 2006 Dec; 48(12):2539-45. PubMed ID: 17174195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
    Brass EP; Cooper LT; Morgan RE; Hiatt WR
    J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of relationship between gait parameters and physical function in peripheral arterial disease.
    Scherer SA; Hiatt WR; Regensteiner JG
    J Vasc Surg; 2006 Oct; 44(4):782-8. PubMed ID: 17012002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Controlled Trial of Allopurinol in Patients With Peripheral Arterial Disease.
    Robertson AJ; Struthers AD
    Can J Cardiol; 2016 Feb; 32(2):190-6. PubMed ID: 26277090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
    Gresele P; Migliacci R; Arosio E; Bonizzoni E; Minuz P; Violi F;
    J Vasc Surg; 2012 Dec; 56(6):1622-8, 1628.e1-5. PubMed ID: 22963812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary evidence that low ankle-brachial index is associated with reduced bilateral hip extensor strength and functional mobility in peripheral arterial disease.
    Parmenter BJ; Raymond J; Dinnen PJ; Lusby RJ; Fiatarone Singh MA
    J Vasc Surg; 2013 Apr; 57(4):963-973.e1. PubMed ID: 23246081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
    Rajagopalan S; Mohler ER; Lederman RJ; Mendelsohn FO; Saucedo JF; Goldman CK; Blebea J; Macko J; Kessler PD; Rasmussen HS; Annex BH
    Circulation; 2003 Oct; 108(16):1933-8. PubMed ID: 14504183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.
    Lewis RJ; Connor JT; Teerlink JR; Murphy JR; Cooper LT; Hiatt WR; Brass EP
    Trials; 2011 May; 12():134. PubMed ID: 21612611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects.
    Hara K; Takahashi N; Wakamatsu A; Caltabiano S
    Drug Metab Pharmacokinet; 2015 Dec; 30(6):410-8. PubMed ID: 26643993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
    Delis KT; Nicolaides AN; Wolfe JH; Stansby G
    J Vasc Surg; 2000 Apr; 31(4):650-61. PubMed ID: 10753272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
    Luo T; Li J; Li L; Yang B; Liu C; Zheng Q; Jin B; Chen Z; Li K; Zhang X; Zhang J
    Thromb Res; 2013 Oct; 132(4):427-32. PubMed ID: 23998557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
    Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
    Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.
    Grossman PM; Mendelsohn F; Henry TD; Hermiller JB; Litt M; Saucedo JF; Weiss RJ; Kandzari DE; Kleiman N; Anderson RD; Gottlieb D; Karlsberg R; Snell J; Rocha-Singh K
    Am Heart J; 2007 May; 153(5):874-80. PubMed ID: 17452167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.